Vernon Osborn
Psychiatric/Mental Health · Gallup, NMNPI 1023491677
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,950 of the $12,276 with a category attached, or 72.9%. Johnson & Johnson accounts for 73.1% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2024 at $9,610 and has fallen 96.4% since, to $348 in 2025. Among psychiatric/mental health clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $111.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$9K
- Gilead$1K
- AbbVie$576
- Organon$154
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$138
- Exact Sciences$121
- plus $1K from 16 others
What the payments were for
- Consulting fees$7406%
- Speaking & faculty fees$8,95073%
- Food & beverage$2,58621%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 3 | $8,979 |
| Gilead | 15 | $1,254 |
| AbbVie | 38 | $576 |
| Organon | 1 | $154 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $138 |
| Exact Sciences | 6 | $121 |
| Biogen | 1 | $118 |
| Otsuka America Pharmaceutical, Inc. | 7 | $117 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $108 |
| Pfizer | 5 | $93 |
| Sanofi Pasteur Inc. | 1 | $90 |
| Insulet Corporation | 3 | $89 |
| Neurocrine Biosciences, Inc. | 4 | $73 |
| Lilly USA, LLC | 4 | $63 |
| Mylan Specialty L.p. | 2 | $62 |
| Abbott | 3 | $59 |
| Viatris Specialty LLC | 2 | $53 |
| Inspire Medical Systems, Inc. | 2 | $42 |
| Novo Nordisk | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| GSK | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,276 in reported general payments places this provider in the 95th percentile of 228 psychiatric/mental health providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 50 | $52,482 |
| JardianceEmpagliflozin | 24 | $44,209 |
| EliquisApixaban | 28 | $43,606 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $41,710 |
| OzempicSemaglutide | 30 | $40,469 |
| JanuviaSitagliptin Phosphate | 26 | $36,006 |
| TrulicityDulaglutide | 13 | $25,146 |
| XareltoRivaroxaban | 15 | $23,292 |
| FarxigaDapagliflozin Propanediol | 12 | $13,979 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $12,082 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $7,681 |
| Atorvastatin Calcium | 346 | $5,207 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $4,140 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $3,906 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 117 | $3,521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $63 | $77,62863 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $16 | $53,79273 claims |
| PfizerEliquis | $93 | $43,60628 claims |
| Novo NordiskOzempic | $30 | $40,46930 claims |
| Johnson & JohnsonXarelto | $8,979 | $23,29215 claims |
| AbbVieSynthroid | $576 | $1,40515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 228 psychiatric/mental health providers in New Mexico.
Other psychiatric/mental health in Gallup
- Ayanna WilliamsRoswell$23K
- Martha SnowAlbuquerque$13K
- Rachel JoyceSanta Fe$13K
- Jacqueline TutonLas Cruces$10K
- Jimmy CalzadoRio Rancho$9K
- Mario HerreraLas Cruces$7K
- Heidi PattarozziLas Cruces$6K
- Lorena GarciaLas Cruces$6K
- Tiny AdamsAlbuquerque$6K
- Boniface GitauClovis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.